Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Karin Tarte, Alicia Beyou, Simon Leonard, Joelle DULONG, Stephane Rodriguez, Noushin Mossadegh-Keller, Gabriel Brisou, Charles BROTTIER, Luc Xerri, Bertrand Nadel, Camille Laurent, Guillaume Cartron, Sandrine Roulland

Blood (2025) 146 (Supplement 1): 553.

https://doi.org/10.1182/blood-2025-553

Published: 2025

Journal Articles

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Mikael Roussel, Juliette Ferrant, Ilenia Camille Manbangui, Simon Le Gallou, Charles BROTTIER, Delphine Rossille, Joelle DULONG, Marie-Helene Delfau, Alexis Claudel, François Lemonnier, Roch Houot, Camille Laurent, Karin Tarte

Blood (2025) 146 (Supplement 1): 5332.

https://doi.org/10.1182/blood-2025-5332

Published: 2025

Journal Articles

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Blood (2025) 146 (Supplement 1): 1958.

https://doi.org/10.1182/blood-2025-1958

Published: 2025

Journal Articles

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

Blood (2025) 146 (Supplement 1): 5923.

https://doi.org/10.1182/blood-2025-5923

Published: 2025

Journal Articles

The Biology of MZL subtypes: Challenge and Relevance of Classification

Camille Laurent, Francesco Bertoni

Blood blood.2024028268.

https://doi.org/10.1182/blood.2024028268

Published: 2025

Includes: Supplemental data

Journal Articles

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Camille Laurent, Preeti Trisal, Bruno Tesson, Sahil Seth, Alicia Beyou, Sandrine Roulland, Bastien Lesne, Nathalie Van Acker, Juan-Pablo Cerapio, Loïc Chartier, Arnaud Guille, Matthew E. Stokes, C. Chris Huang, Sarah Huet, Anita K. Gandhi, Franck Morschhauser, Luc Xerri

Blood (2024) 144 (24): 2503–2516.

https://doi.org/10.1182/blood.2024024496

Published: 2024

Includes: Supplemental data

Journal Articles

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Blood (2024) 144 (Supplement 1): 1597.

https://doi.org/10.1182/blood-2024-209815

Published: 2024

Journal Articles

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Blood (2024) 144 (Supplement 1): 4505.

https://doi.org/10.1182/blood-2024-200614

Published: 2024

Journal Articles

Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm

Camille Laurent, Sascha Dietrich, Karin Tarte

Blood (2024) 143 (12): 1080–1090.

https://doi.org/10.1182/blood.2023021000

Published: 2024

Journal Articles

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Blood (2023) 142 (Supplement 1): 848.

https://doi.org/10.1182/blood-2023-173929

Published: 2023

Journal Articles

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Blood (2023) 142 (Supplement 1): 893.

https://doi.org/10.1182/blood-2023-177703

Published: 2023

Journal Articles

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Blood (2023) 142 (Supplement 1): 4439.

https://doi.org/10.1182/blood-2023-188896

Published: 2023

Journal Articles

Identification of MYC -Driven High-Grade B-Cell Lymphoma Using Deep Learning-Based Whole Slide Image Analysis

Anil Yüce, Christian Doerig, Jacob Gildenblat, Samaneh Abbasi-Sureshjani, Agata Mosinska, Heather Wright, Wilfred Leung, Yanwen Jiang, Patrick Kimes, Camille Laurent, Konstanty Korski, Markus D Herrmann

Blood (2023) 142 (Supplement 1): 3649.

https://doi.org/10.1182/blood-2023-188648

Published: 2023

Journal Articles

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Alexandra Traverse-Glehen, Laurent Martin, Camille Laurent, Peggy Dartigues, Barbara Burroni, Diane Damotte, Marie Parrens, Herve Ghesquieres, Marguerite Fournier, Salim Kanoun, Anne Ségolène Cottereau, Marc Andre, Cédric Rossi, René-Olivier Casasnovas

Blood (2023) 142 (Supplement 1): 3011.

https://doi.org/10.1182/blood-2023-174784

Published: 2023

Journal Articles

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Blood (2023) 142 (Supplement 1): 297.

https://doi.org/10.1182/blood-2023-185057

Published: 2023

Journal Articles

Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey

Blood (2022) 140 (24): 2573–2583.

https://doi.org/10.1182/blood.2022015520

Published: 2022

Includes: Supplemental data

Journal Articles

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Yuta Ito, Amira Marouf, Yasunori Kogure, Junji Koya, Mariko Tabata, Yuki Saito, Sumito Shingaki, Mitsuhiro Yuasa, Kentaro Yamaguchi, Julie Bruneau, Manon Vavasseur, Michaël Dussiot, Isabelle Andre, Akshay Joshi, Chantal Lagresle-Peyrou, Aude Magerus, Sammara Chaubard, David Lavergne, Emmanuel Bachy, Erika Brunet, Virginie Fataccioli, Chantal Brouzes, Camille Laurent, Laurence De Leval, Alexandra Traverse-Glehen, Céline Bossard, Marie Parrens, Véronique Meignin, Laure Philippe, Julien Rossignol, Felipe Suarez, Jean-Marie Michot, Olivier Tournilhac, Christine Bole-Feysot, Patrick Nitschke, Bruno Tesson, Cécile Laurent, Thierry Jo Molina, Vahid Asnafi, Sachiko Tsukita, Koji Izutsu, Hiroaki Miyoshi, Seiji Sakata, Akito Dobashi, Kengo Takeuchi, Koichi Ohshima, Philippe Gaulard, Arnaud Jaccard, Seishi Ogawa, Olivier Hermine, Keisuke Kataoka, Lucile Couronne

Blood (2022) 140 (Supplement 1): 1737–1739.

https://doi.org/10.1182/blood-2022-159869

Published: 2022

Journal Articles

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

Roch Houot, Emmanuel Bachy, Guillaume Cartron, François-Xavier Gros, Franck Morschhauser, Lucie Oberic, Thomas Gastinne, Pierre Feugier, Remy Dulery, Catherine Thieblemont, Magalie Joris, Francisco Llamas-Gutierrez, Emmanuel Itti, Cedric Menard, Yassine Al-Tabaa, Clement Bailly, Marie-Helene Delfau, Camille Laurent, Francois Lemonnier

Blood (2022) 140 (Supplement 1): 410–411.

https://doi.org/10.1182/blood-2022-156626

Published: 2022

Journal Articles

A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

Herve Ghesquieres, Youenn Drouet, Susan L. Slager, Franck Morschhauser, Sara Galimberti, Dennis P. Robinson, Emilie Thomas, Anne J. Novak, Luc Xerri, Stefano Luminari, Aurelie Verney, Camille Laurent, Lisa M. Rimsza, Thomas M. Habermann, Massimo Federico, Brian K. Link, Gilles Salles, James R. Cerhan

Blood (2022) 140 (Supplement 1): 1307–1309.

https://doi.org/10.1182/blood-2022-167466

Published: 2022

Journal Articles

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Elias Campo, Elaine S. Jaffe, James R. Cook, Leticia Quintanilla-Martinez, Steven H. Swerdlow, Kenneth C. Anderson, Pierre Brousset, Lorenzo Cerroni, Laurence de Leval, Stefan Dirnhofer, Ahmet Dogan, Andrew L. Feldman, Falko Fend, Jonathan W. Friedberg, Philippe Gaulard, Paolo Ghia, Steven M. Horwitz, Rebecca L. King, Gilles Salles, Jesus San-Miguel, John F. Seymour, Steven P. Treon, Julie M. Vose, Emanuele Zucca, Ranjana Advani, Stephen Ansell, Wing-Yan Au, Carlos Barrionuevo, Leif Bergsagel, Wing C. Chan, Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando Lopez-Guillermo, Maria Victoria Mateos, Elizabeth Macintyre, Ari M. Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano A. Pileri, Miguel Piris, Barbara Pro, Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier-Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz

Blood (2022) 140 (11): 1229–1253.

https://doi.org/10.1182/blood.2022015851

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Longitudinal single-cell profiling of the bone marrow heterogeneity identifies the T-cell niche supporting cancer persister cells in follicular lymphoma

Circulating CD161high CD8 T cells at leukapheresis are associated with reduced risk of progression at 12 months (PFS12) in large B-cell lymphoma treated by axicabtagene ciloleucel: Results from the Phase 2 alycante study (LYSA)

Glofitamab is superior to non a-CD3xC20 treatments for patients with diffuse large B-cell lymphoma who are refractory or relapse immediately after anti-CD19 CAR T-cell therapy: Final results of the bicar study (LYSA) and indirect comparison with a synthetic control arm from the descart registry.

Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.

The Biology of MZL subtypes: Challenge and Relevance of Classification

Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significance

Single-Cell Atlas of Diffuse Large B-Cell Lymphoma Reveals Integrated Malignant B Cell and Tumor Microenvironment Characteristics Associated with Clinical Response

Health-Related Quality of Life after Axi-Cel As a Second-Line Therapy in Patients with High-Risk Relapsed/Refractory Large B-Cell Lymphoma Who Are Ineligible for Autologous Stem Cell Transplantation: Results of the Alycante Phase II Trial

Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm

A Single Cell Atlas of Diffuse Large B Cell Lymphomas Reveals Distinct Cellular States Predictive of Outcomes

Glofitamab Monotherapy in Patients with Non-Hodgkin B-Cell Lymphoma after Failing CAR T-Cell Infusion: Primary Analysis of the Bicar Study, a Phase II Lysa Study

Impact of Brentuximab Vedotin in Patients with Breast Implant-Associated Anaplastic Large Cell Lymphoma with Capsule Infiltration Requiring Chemotherapy

Identification of MYC -Driven High-Grade B-Cell Lymphoma Using Deep Learning-Based Whole Slide Image Analysis

CD20low/CD68high a Promising Microenvironnement Profile Identifying Classical Hodgkin Lymphoma Patients with Poor Outcome a Lysa Study

Tazemetostat in Combination with R-CHOP in Patients with High-Risk, Frontline Follicular Lymphoma (Epi-RCHOP): A Phase II Study from the Lysa

Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey

Frequent Alterations of Driver Genes in Chromosome X and Their Clinical Relevance in Extranodal NK/T-Cell Lymphoma

Axicabtagene Ciloleucel As Second-Line Therapy for Large B-Cell Lymphoma in Transplant-Ineligible Patients: Primary Analysis of Alycante, a Phase 2 Lysa Study

A Genome-Wide Association Study (GWAS) of Event-Free Survival (EFS) in Follicular Lymphoma Patients Treated with Front-Line Immunochemotherapy: A Lysa, Iowa/Mayo MER, and FIL Study

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only